WO2000000603A3 - Modularly constructed rna molecules having two sequence region types - Google Patents

Modularly constructed rna molecules having two sequence region types Download PDF

Info

Publication number
WO2000000603A3
WO2000000603A3 PCT/DE1999/001867 DE9901867W WO0000603A3 WO 2000000603 A3 WO2000000603 A3 WO 2000000603A3 DE 9901867 W DE9901867 W DE 9901867W WO 0000603 A3 WO0000603 A3 WO 0000603A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna molecules
rna
sequence region
relates
modularly constructed
Prior art date
Application number
PCT/DE1999/001867
Other languages
German (de)
French (fr)
Other versions
WO2000000603A2 (en
Inventor
Annemarie Poustka
Johannes Coy
Original Assignee
Deutsches Krebsforsch
Annemarie Poustka
Johannes Coy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Annemarie Poustka, Johannes Coy filed Critical Deutsches Krebsforsch
Priority to EP99939955A priority Critical patent/EP1090115A2/en
Priority to AU54076/99A priority patent/AU5407699A/en
Priority to CA002332175A priority patent/CA2332175A1/en
Publication of WO2000000603A2 publication Critical patent/WO2000000603A2/en
Publication of WO2000000603A3 publication Critical patent/WO2000000603A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Abstract

The invention relates to modularly constructed RNA molecules which can bind to a ligand and which are characterized by two sequence regions. Said first sequence region contributes to the maintenance of the three-dimensional structure of the RNA molecule, and a second sequence region is responsible for the specific bond of the ligand. These RNA molecules, e.g. the NINTROX-RNA, can be used for directly influencing the gene expression. The invention also relates to vectors containing the inventive RNA molecules, to medicaments and diagnostic compositions which contain said RNA molecules or vectors, to an antibody which specifically recognizes these RNA molecules or antisense RNA which specifically binds to these RNA molecules, or to ribozymes which split these RNA molecules. In addition, the invention relates to non-human mammals whose NINTROX gene is modified by inserting a heterologous sequence and to the cells obtained therefrom.
PCT/DE1999/001867 1998-06-26 1999-06-25 Modularly constructed rna molecules having two sequence region types WO2000000603A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99939955A EP1090115A2 (en) 1998-06-26 1999-06-25 Modularly constructed rna molecules having two sequence region types
AU54076/99A AU5407699A (en) 1998-06-26 1999-06-25 Modularly constructed rna molecules having two sequence region types
CA002332175A CA2332175A1 (en) 1998-06-26 1999-06-25 Modularly constructed rna molecules having two sequence region types

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19828624.4 1998-06-26
DE19828624A DE19828624C1 (en) 1998-06-26 1998-06-26 Modular RNA molecules with two sequence region types

Publications (2)

Publication Number Publication Date
WO2000000603A2 WO2000000603A2 (en) 2000-01-06
WO2000000603A3 true WO2000000603A3 (en) 2000-04-13

Family

ID=7872174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/001867 WO2000000603A2 (en) 1998-06-26 1999-06-25 Modularly constructed rna molecules having two sequence region types

Country Status (5)

Country Link
EP (1) EP1090115A2 (en)
AU (1) AU5407699A (en)
CA (1) CA2332175A1 (en)
DE (1) DE19828624C1 (en)
WO (1) WO2000000603A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010228A1 (en) * 1991-11-12 1993-05-27 Synaptic Pharmaceutical Corporation Dna encoding a glycine transporter and uses thereof
WO1995024503A1 (en) * 1994-03-07 1995-09-14 Rapaport, Erich Sensitive cancer test

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010228A1 (en) * 1991-11-12 1993-05-27 Synaptic Pharmaceutical Corporation Dna encoding a glycine transporter and uses thereof
WO1995024503A1 (en) * 1994-03-07 1995-09-14 Rapaport, Erich Sensitive cancer test

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
REICHWALD ET AL.: "Homo sapiens chromosome X, Mecp2 locus, complete sequence", EMBL SEQUENCE DATABASE, 6 April 1998 (1998-04-06), HEIDELBERG DE, XP002130191 *
REICHWALD ET AL.: "Homo sapiens chromosome X, PAC 671D9, complete sequence", EMBL SEQUENCE DATABASE, 6 April 1998 (1998-04-06), HEIDELBERG DE, XP002130190 *
SEAGER ET AL.: "Introductory Chemistry. General, Organic, Biological", 1979, SCOTT, FORESMAN AND COMPANY, GLENVIEW, ILLINOIS, CHAPTER 25.7 THE RNAS, SEITE 497-503,, XP002130192 *

Also Published As

Publication number Publication date
AU5407699A (en) 2000-01-17
WO2000000603A2 (en) 2000-01-06
EP1090115A2 (en) 2001-04-11
DE19828624C1 (en) 2000-02-24
CA2332175A1 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
WO2002020569A3 (en) Mammalian genes; related reagents and methods
Paquet et al. Branch specificity of purified rat liver Golgi UDP-galactose: N-acetylglucosamine beta-1, 4-galactosyltransferase. Preferential transfer of of galactose on the GlcNAc beta 1, 2-Man alpha 1, 3-branch of a complex biantennary Asn-linked oligosaccharide.
Mallinson et al. Identification and partial characterization of the human erythrocyte membrane component (s) that express the antigens of the LW blood-group system
EP2305715A3 (en) Monoclonal antibody to osteoprotegerin binding protein
WO2001045746A3 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
WO1999061619A3 (en) Cell cycle genes, proteins and uses thereof
WO2005097185A3 (en) Irta-5 antibodies and their uses
Johnson et al. Purification of the Lewis blood-group gene associated α-3/4-fucosyltransferase from human milk: an enzyme transferring fucose primarily to type 1 and lactose-based oligosaccharide chains
WO2005000901A3 (en) Cd20-specific antibodies and methods of employing same
DE69619493T2 (en) POLYPEPTIDE-DENDRIMER COMPLEXES
EP0876396A4 (en) MIMOTOPES AND ANTI-MIMOTOPES OF HUMAN PLATELET GLYCOPROTEIN Ib/IX
DE69602809T2 (en) Transport vehicle for macromolecules
Esteban Warren et al. Electrospray ionization tandem mass spectrometry of model peptides reveals diagnostic fragment ions for protein ubiquitination
WO2002094853A3 (en) Antibodies specific for poly(ethylene glycol)
IL125081A0 (en) Ob protein receptor and related compositions and methods
Imber et al. Clearance and binding of native and defucosylated lactoferrin
WO2000000603A3 (en) Modularly constructed rna molecules having two sequence region types
MX9602557A (en) Proteins from mammalian liver and their use in oncology.
DE69637941D1 (en) MODIFIED HEMOGLOBINARY COMPOUNDS AND METHOD FOR CLEANING THEM
Santer et al. Presence of fucosyl residues on the oligosaccharide antennae of membrane glycopeptides of human neuroblastoma cells
Ogawa et al. Profiling terminal N-acetyllactosamines of glycans on mammalian cells by an immuno-enzymatic assay
ATE110469T1 (en) NON SEPARATE SOLID PHASE ENZYME ASSAY.
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods
CN101967181B (en) Method for accumulating cotton phosphorylated protein
Kirby et al. Ion Pairing Techniques: Compatibility with On-Line Liquid Chromatography—Mass Spectrometry

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2332175

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999939955

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999939955

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09720215

Country of ref document: US

ENP Entry into the national phase

Ref country code: US

Ref document number: 2001 720215

Date of ref document: 20010711

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999939955

Country of ref document: EP